OPKO Health, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
OPKO Health, Inc. (OPK) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $82.40 million for the 12-month period ending 2017-12-31, per its 8-K filed 2019-01-29.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2019-01-29
- OPKO Health, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-12-31 was $0.00.
- OPKO Health, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-09-30 was $93.40M.
- OPKO Health, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was -$93.40M, a 200.00% decline from fiscal 2015.
- OPKO Health, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $93.40M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2017-12-31 | $82.40M 8-K · filed 2019-01-29 | |||
| 2016-12-31 | -$93.40M 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $93.40M derived: sum of 2 quarters · filed 2016-11-07 | $93.40M 10-K · filed 2016-02-29 | |
| 2015-09-30 | $93.40M 10-Q · filed 2016-11-07 | $93.40M 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |